Theriva Biologics Inc. (NYSE AMERICAN: TOVX)
$0.26
+0.0023 ( +0.89% ) 154.0K
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Market Data
Open
$0.26
Previous close
$0.26
Volume
154.0K
Market cap
$4.73M
Day range
$0.25 - $0.28
52 week range
$0.20 - $0.75
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | May 23, 2024 |
8-k | 8K-related | 13 | May 16, 2024 |
8-k | 8K-related | 15 | May 07, 2024 |
10-q | Quarterly Reports | 71 | May 07, 2024 |
8-k | 8K-related | 14 | May 02, 2024 |
8-k | 8K-related | 17 | Apr 23, 2024 |
8-k | 8K-related | 17 | Apr 22, 2024 |
8-k | 8K-related | 60 | Apr 16, 2024 |
8-k | 8K-related | 20 | Mar 25, 2024 |
10-k | Annual reports | 122 | Mar 25, 2024 |